Here are relevant reports on : glp-1-receptor-agonist-market
-
Opioids Market by Product (Morphine, Codeine, Fentanyl, Meperidine), Receptor Binding (Strong Agonist, Mild to Moderate Agonist), Application (Pain Management, Cough Supression, Diarrhea Suppresion), Region (North America, Europe, Asia, RoW) - Global Forecasts to 2023
Opioids are a group of narcotic pain-relieving drug which act by interacting with opioid receptors in cells. Opioids can be made from the poppy plant such as, morphine or synthesized in a laboratory such as fentanyl. It is used as an anesthesia, cough suppressant, diarrhea suppressant and for the management of pain arising from various disease.
- Published: January 2026
- Price: $ 4950
- TOC Available:
-
Pulmonary Arterial Hypertension Market by Drug Class (SGC Stimulators, Endothelin Receptor Antagonists, Type (Innovative, Generics) – Global Forecast to 2027
The global pulmonary arterial hypertension market is projected to reach USD 9 billion by 2027 from USD 7 billion in 2022, at a CAGR of 5% during the forecast period
- Published: January 2026
- Price: $ 4950
- TOC Available:
-
Parkinson's Disease Treatment Market by Drug Class (Carbidopa/Levodopa, Dopamine Receptor Agonists, MAO-Inhibitors), Distribution Channel (Hospital, Online, Retail Pharmacies), Patient Care Setting (Hospitals, Clinics) - Global Forecast to 2022
The Parkinson's disease treatment market is expected to reach USD 5.69 Billion by 2022 from USD 4.24 Billion in 2017, at a CAGR of 6.1%. The market is being driven by the growth in aging population and the associated increase in the prevalence of Parkinson’s disease and government funding for research. Some of the major players operating in the Parkinson’s disease treatment market include Teva (Israel), Novartis AG (Switzerland), GSK (UK), AbbVie (US), Merck (US), Boehringer Ingelheim (Germany), Impax Laboratories (US), Lundbeck (Denmark), Sun Pharma (India), Wockhardt (India), UCB (Belgium), Valeant Pharmaceuticals (Canada), and Acadia (US).
- Published: October 2017
- Price: $ 4950
- TOC Available:
-
Oral Proteins & Peptides Market by Molecule (Semaglutide, Linaclotide, Calcitonin), Drug Class (GLP-1, GPE, CGRP), Therapeutic Area (Nephrology, Gastroenterology, Genetic, CNS, Obesity, Diabetes), Formulation (Tablet, Capsule) - Global Forecast to 2030
The global oral proteins and peptides market, valued at US$8.07 billion in 2024, stood at US$9.31 billion in 2025 and is projected to advance at a resilient CAGR of 16.4% from 2025 to 2030, culminating in a forecasted valuation of US$19.93 billion by the end of the period. This growth is driven by several factors, including the rising prevalence of chronic diseases such as diabetes, gastrointestinal disorders, and kidney diseases.
- Published: February 2025
- Price: $ 4950
- TOC Available:
-
Biosimilars Market by Drug Class (mAbs (Adalimumab, Infliximab, Rituximab, Trastuzumab), GCSF, Insulin, Anticoagulant, rhGH, Teriparatide, GLP-1), Indication (Oncology, Autoimmune, Diabetes, Obesity), Competitive Landscape, Region - Global Forecast to 2035
The global biosimilars market, valued at US$32.75 billion in 2024, stood at US$35.04 billion in 2025 and is projected to advance at a resilient CAGR of 7.5% from 2025 to 2035, culminating in a forecasted valuation of US$72.29 billion by the end of the period. This growth is driven by several key factors, including a rising number of regulatory approvals and product launches, the patent expiries of major biologics, and the increasing prevalence of chronic diseases that require effective and affordable treatment options.
- Published: June 2025
- Price: $ 4950
- TOC Available:
-
GLP-1 Agonists Market by Product (Ozempic, Wegovy, Mounjaro), Molecule (semaglutide, tirzepatide), Type (Patented, Biosimilars), Format (Single dose, Multi-dose, Tablets), ROA (SC, Oral), Indication (Diabetes, Obesity) - Global Forecast to 2033
The global GLP-1 analogues market, valued at US$53.74 billion in 2024, stood at US$64.42 billion in 2025 and is projected to advance at a resilient CAGR of 13.0% from 2025 to 2033, culminating in a forecasted valuation of US$170.75 billion by the end of the period. The market for GLP-1 agonists is highly consolidated, with key players strategizing to capture the market. Prominent players in the GLP-1 agonists market are Novo Nordisk (Denmark), Eli Lilly (US), and Sanofi (France), among other players.
- Published: October 2025
- Price: $ 4950
- TOC Available:
-
Injection Pen Market Size, Share & Trends by Type (Disposable and Reusable Pens), Therapy (Diabetes Therapy (Insulin, GLP-1), Growth Hormone Therapy, Osteoporosis, obesity, fertility), End User (Homecare and Hospitals & Clinics), and Region - Global Forecast to 2030
The global injection pen market, valued at US$43.8 billion in 2023, stood at US$47.0 billion in 2025 and is projected to advance at a resilient CAGR of 7.9% from 2024 to 2030, culminating in a forecasted valuation of US$74.1 billion by the end of the period. The surging cases of chronic diseases globally, the launch and approval of new, advanced products, the growing trend towards smart devices, and favorable developments in government policies to promote low-cost injections will stimulate market growth.
- Published: August 2024
- Price: $ 4950
- TOC Available:
-
Bluetooth Smart and Smart Ready Market by Technology (Bluetooth Smart, Smart Ready, and Bluetooth 5.0), Application (Automotive, Consumer Electronics, Wearable Electronics, Healthcare, Building & Retail), and Geography - Global Forecast to 2023
The Bluetooth Smart and Smart Ready market was valued at USD 4.55 Billion in 2016 and is expected to reach USD 5.34 Billion by 2023, at a CAGR of 2.23% during the forecast period. Growth of this market is being fueled by technological advancements over the past few years. Some of the major companies operating in the Bluetooth Smart and Smart Ready market are Qualcomm Inc. (US), Broadcom Corporation (Singapore), Cypress Semiconductor Corporation (US), Dialog Semiconductor PLC (UK), Marvell Technology Group, Ltd. (Bermuda), Mediatek, Inc. (Taiwan), Nordic Semiconductor ASA (Norway), Bluegiga Technologies (Finland), Texas Instruments Incorporated (US), Fanstel Corporation (US), Toshiba Corporation (Japan), Murata Manufacturing Co., Ltd. (Japan), Renesas Electronics Corporation (Japan), Microchip Technology Inc. (US), and CEVA, Inc. (US).
- Published: June 2017
- Price: $ 4950
- TOC Available:
-
Field Force Automation Market by Component (Solution and Services), Organization Size, Deployment Type, Industry (IT and Telecom, Energy and Utilities, Manufacturing, and Transportation and Logistics), and Region - Global Forecast to 2024
Field Force Automation Market is expected to grow USD 2.8 billion by 2024, at a Compound Annual Growth Rate (CAGR) of 18.2% during the forecast period. The field force automation market comprises significant solution providers, such as ServiceMax (US), IFS (Sweden), Microsoft (US), SAP (Germany), Oracle (US), Trimble (US), ClickSoftware (US), Salesforce (US), Astea (US), FieldEZ (India), BT, Accruent (US), Acumatica (US), Folio3 (US), LeadSquared (India), Kloudq (India), Appobile Labs (India), Mize (US), Nimap Infotech (India), and Channelplay (India). The study includes the in-depth competitive analysis of these key players in the field force automation market with their company profiles, recent developments, and key market strategies.
- Published: October 2019
- Price: $ 4950
- TOC Available:
-
IR Spectroscopy Market Size, Share, Statistics, Industry Growth Analysis by Technology (FTIR, Dispersive IR), Type (Near-infrared Spectroscopy, Mid-infrared Spectroscopy), Product Type (Benchtop Spectroscopes), End-user Industry (Healthcare & Pharmaceutical, Chemicals) - Global Forecast to 2029
The global IR spectroscopy market is expected to grow from USD 1.2 billion in 2024 to USD 1.6 billion by 2029, at a compound annual growth rate (CAGR) of 6.5% during the forecast period.The key players Shimadzu Corporation (Japan); ZEISS (Germany); PerkinElmer Inc. (US); Agilent Technologies, Inc. (US); Bruker Corporation (US).
- Published: March 2024
- Price: $ 4950
- TOC Available:
Records 1 to 10 of 50
